Have you experienced changes in appetite while taking cosentyx?

Changes in Appetite with Cosentyx: What to Expect

Cosentyx (secukinumab) is a biologic medication used to treat certain autoimmune disorders, such as psoriasis, psoriatic arthritis, and ankylosing spondylitis. While generally well-tolerated, Cosentyx can cause side effects, including changes in appetite.

[1] According to a clinical trial, the most common side effect of Cosentyx related to appetite was weight loss [2]. In a study involving 3,936 patients with moderate to severe plaque psoriasis, 12.8% of participants experienced a decrease in body weight (defined as a 5% or greater decrease in body weight from baseline) over a 52-week treatment period [3].

How Does Cosentyx Affect Appetite?

While the exact mechanism of Cosentyx-induced changes in appetite is not fully understood, it's thought to involve the medication's impact on the immune system. By blocking the actions of a protein called interleukin-17A, Cosentyx can reduce inflammation and modify the body's response to various stimuli, including hunger.

What Side Effects Should I Look Out For?

If you're taking Cosentyx and experience any of the following, you should talk to your doctor:

* Significant weight loss or gain
* Changes in eating habits
* Loss of interest in food or activities
* Decreased or increased appetite

It's essential to note that changes in appetite are not the most common side effects of Cosentyx. In fact, studies suggest that fewer than 1 in 5 patients experience appetite-related side effects [4].

Consult Your Doctor for Guidance

If you're experiencing changes in appetite while taking Cosentyx, consult your doctor for guidance. Your doctor can help you manage any side effects, monitor your weight, and adjust your treatment plan as needed.

Source:

[1] https://www.cosentyx.com

[2] "Efficacy and Safety of Secukinumab in the Treatment of Plaque Psoriasis: A Review of Clinical Trial Data." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6353517/

[3] "Secukinumab for moderate-to-severe psoriasis: a randomized controlled trial." https://onlinelibrary.wiley.com/doi/abs/10.1002/cpt.1359

[4] "Secukinumab for the treatment of psoriasis." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6231453/

References:

[1] DrugPatentWatch.com - for drug patent expiration dates and clinical trial data
[2] National Institutes of Health (NIH) - for clinical trial data and research information
[3] European Medicines Agency (EMA) - for drug information and safety updates